15-Hydroxyprostaglandin dehydrogenase suppresses K-RasV12-dependent tumor formation in Nu/Nu mice

Hung Pham1, Guido Eibl, Romina Vincenti

  • 1Department of Medicine, Division of Digestive Diseases, University of California, Los Angeles, California, USA.

Molecular Carcinogenesis
|December 7, 2007
PubMed

Insights

Overexpressing 15-hydroxyprostaglandin dehydrogenase (PGDH) suppresses K-Ras mutations in colorectal cancer. PGDH reduces prostaglandin E2 (PGE2) levels, inhibiting tumor growth and promoting apoptosis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Oncogenic Ras mutations are early events in colorectal cancer (CRC).
  • Ras mutations induce cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) biosynthesis, promoting cancer progression.
  • 15-hydroxyprostaglandin dehydrogenase (PGDH) degrades PGE2 and is downregulated in CRC, suggesting a tumor-suppressive role.

Purpose of the Study:

  • To investigate the role of PGDH in suppressing K-Ras-mediated tumorigenesis in intestinal epithelial cells.
  • To determine if PGDH overexpression can attenuate the effects of oncogenic K-Ras.

Main Methods:

  • Lentiviral transduction was used to express K-Ras(V12) and/or PGDH in rat intestinal epithelial cells (IEC-18).
  • Cell proliferation, anchorage-independent growth (soft agar assay), and tumor formation in xenografts were assessed.
  • Levels of COX-2, microsomal prostaglandin E synthase-1 (mPGES-1), PGE2, and PGI2 were measured.

Main Results:

  • K-Ras(V12) expression increased proliferation, COX-2/mPGES-1 expression, and PGE2/PGI2 levels.
  • PGDH overexpression in K-Ras(V12) cells significantly decreased proliferation, COX-2/mPGES-1 expression, and PGE2/PGI2 levels.
  • Xenografts of K-Ras(V12) cells formed rapid tumors, while those with PGDH overexpression showed delayed tumor formation, reduced proliferation, and increased apoptosis.

Conclusions:

  • PGDH expression suppresses K-Ras(V12)-mediated tumorigenesis in intestinal epithelial cells.
  • PGDH attenuates Ras-driven colorectal cancer progression by reducing PGE2 levels.
  • PGDH represents a potential therapeutic target for colorectal cancer.